Drug name: Mitoxantrone + Vismodegib

Cas.no	PubChem ID
65271-80-9	4212

Known Target
DNA
DNA topoisomerase 2-alpha	P11388
Structure
Zoom In
Introduction
Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.

Cas.no	PubChem ID
879085-55-9	24776445

Known Target
Smoothened homolog	Q99835
Structure
Zoom In
Introduction
Vismodegib (trade name Erivedge) is a drug for the treatment of basal-cell carcinoma (BCC). It acts as a cyclopamine-competitive antagonist of the smoothened receptor (SMO) which is part of the hedgehog signaling pathway. SMO inhibition causes the transcription factors GLI1 and GLI2 to remain inactive, which prevents the expression of tumor mediating genes within the hedgehog pathway. This pathway is pathogenetically relevant in more than 90% of basal-cell carcinomas.

• [1] Hedgehog pathway inhibitor HhAntag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Zhang, Y., et al. (2009).Neoplasia.11(1):96-101.
  19107236. [ 19107236 ]